1
2
D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3
5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10% 4 5g/kg / 24 () 45 515 15 15% () 21 16 5 2 D- 1 3 7.5g22.5g/3 D- 22.5g/ 1 MCV MCV MCHC 22.5g 22.5g () 4
12 D- 15g45/ HDL D- 2 () 8 ( 4 )2 8 ( 4 ) D- 75g/ (25g3 ) 8 30 60 3 7 6 12 28 D 15g45g/ 45 6 D 07.515.022.530.0g 30 3060 90120 D- 30g 22.5g 8 8 2 75g D- 75g D- 75g OGTT 2 AUC 2 5 75 D- 75g OSTT 2 10 D- 1030g D- 75g () 2 12 11 9 2 5
D- 7.5g 30 180 180 D- 75g 30 210 60 240 2 12 D 75g (OGTT) 180 30 180 210 240 D D-1- ATP D- 30 31 30 D--1- ATP 150 D 50 230 D- 30g () 8 D- 75g/ 2 SU 2 23 SU 11 12 3 7.5g -() 1 6
D- 7
8
9
20 2 195832:802-805. 10
Levin GV, Zehner LR, Saunders JP, Beadle JR. Sugar substitutes: their energy values, bulk characteristics, and potential health benefits. Am. J. Clin. Nutr.(1995) 62: 1161S-8S. FDA. Agency response letter GRAS Notis No.GRN 000078.(2001). Joint FAO/WHO expert committee on food additives sixty-third meeting. Summary and conclusions. ftp://ftp.fao.org/es/esn/jecfa/jecfa63_summary.pdf Kruger CL, Whittaker MH, Frankos VH. Genotoxicity tests on D-tagatose. Regulatory Toxicology and Pharmacology (1999)29: S36-S42. Acute Oral Toxicity Study in rats and mice. (1989).() Kruger CL, Whittaker MH, Frankos VH, Trimmer GW. 90day oral toxicity study of D-tagatose in rats. Regulatory Toxicology and Pharmacology(1999) 29: S1-S10. Kruger CL, Whittaker MH, Frankos VH, Schroeder RE. Development toxicity study of D-tagatose in rats. Regulatory Toxicology and Pharmacology(1999) 29: S28-S35. Lina BAR, Kuper CF. Chronic toxicity and carcinogenicity study with D-tagatose and fructose in Wistar ratstno Nutrition and Food Research(2002)4533..(2002),,,,, D-(No.3): 3. (200526:287-296. Donner TW, Wilber JF. 1year administration study of D-tagatose in adults with type 2 diabetes. Diabetes, obesity and metabolism. Sauders JP, Donner TW, Sadler JH, Levin GV, Makris NG. Effect of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans. Regulatory Toxicology and Pharmacology.(1999)29:S57-S65. Boesch C, Ith M, Jung B, Bruegger K, Erban S, Diamantis I, Kreis R, Bar A. Effects of oral D-tagatose on liver volume and hepatic glycogen accumulation in healthy male volunteers. Regulatory Toxicology and Pharmacology (2001)33: 257-267.,,,,..(2006)27:267-273. Donner TW, Wilber JF, Ostrwski D. D-tagatose, a novel hexose : acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes, Obesity and Metabolism. (1999)1: 285-291. Buemann B, Gesmar H, Astrup A, Quistorff B. Effects of oral D-tagatose, a stereoisomer of D-fructose, on liver metabolism in man as examined by 31P-magnetic resonance spectroscopy. Metabolism(2000)49: 1335-1339. D-. (2005)() 2 D-. (2005) () Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS. The efficacy of acarbose in the treatment of patients with non-insulindependent diabetes mellitus. Ann.Intern. Med.(1994)121: 928-935 21 Buemann B, Toubro S, Holst JJ, Rehfeld JF, Bibby BM, Astrup A, D-tagatose, a stereoisomer of D-fructose, increases blood uric acid concentration. Metabolism (2000)49:969-976. 11
22 Effect of an oral 30g dose of D-tagatose on the plasma uric acid levels of healthy male volunteers. (2001).() 23 Effect of oral 15g dose of D-tagatose on the plasma uric acid levels of hyperuricemic male volunteers. (2002).() 24 Final assessment report application A472, D-tagatose as a novel food. Food Standards Australia New Zealand (2004). 12